USCOM Ltd
UCM
Company Profile
Business description
USCOM Ltd is engaged in the development, design, manufacture, and marketing of premium non-invasive cardiovascular and pulmonary medical devices. The company's geographical segment includes Australia, Asia, America, Europe, and Other regions. The company generates maximum revenue from Australia. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, SPIROSONIC, a pulmonary function testing device based on multi-path ultrasound technology.
Contact
66 Clarence Street
Suite 2, Level 8
SydneyNSW2000
AUST: +61 292474144
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
11
Stocks News & Analysis
stocks
AI stocks winners, laggards and losers for 2025
AI stocks flew high in 2025 despite year-end volatility. Palantir and Lam look overvalued, but opportunities remain.
stocks
12 picks for an income portfolio - Q4 2025 update
Eighteen months in and passive income growth has exceeded my target.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,092.70 | 25.50 | 0.28% |
| CAC 40 | 8,317.07 | 45.02 | -0.54% |
| DAX 40 | 25,262.38 | 0.74 | 0.00% |
| Dow JONES (US) | 49,504.07 | 237.96 | 0.48% |
| FTSE 100 | 10,113.12 | 11.48 | -0.11% |
| HKSE | 26,608.48 | 376.69 | 1.44% |
| NASDAQ | 23,671.35 | 191.33 | 0.81% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,683.29 | 12.96 | -0.09% |
| S&P 500 | 6,966.28 | 44.82 | 0.65% |
| S&P/ASX 200 | 8,759.40 | 25.80 | 0.30% |
| SSE Composite Index | 4,165.29 | 44.86 | 1.09% |